Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |18 February 2003

Interferon Therapy Improves Survival in Patients with Liver Cancer and Hepatitis C Virus Infection

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. It is in the 18 February 2003 issue of Annals of Internal Medicine (volume 138, pages 299-306). The authors are Y Shiratori, S Shiina, T Teratani, M Imamura, S Obi, S Sato, Y Koike, H Yoshida, and M Omata.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What are the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

What is the problem and what is known about it so far?

Some infections of the liver are caused by hepatitis C virus (HCV). Hepatitis C produces scar tissue in the liver, a condition known as cirrhosis. Cirrhosis is closely associated with the development of liver cancer. Doctors have observed that the risk for liver cancer decreases when patients with HCV infection are given the antiviral medication interferon. However, liver cancer is very difficult to cure. One of the treatments used to treat liver cancer involves injecting the cancerous nodules with alcohol, which kills the tumor cells. But even after the tumor cells have been killed, the cancer tends to recur. Doctors don't know whether patients with HCV infection who already have liver cancer will benefit from interferon treatment in addition to alcohol injections.

Why did the researchers do this particular study?

They wanted to see if treatment with a combination of interferon and repeated alcohol injections into recurring tumors nodules could increase survival in patients with both HCV and liver cancer.

Who was studied?

49 patients with mild HCV infection and three or fewer liver cancer nodules that had already been treated once with alcohol injections.

How was the study done?

After the researchers confirmed that the tumor nodules had been destroyed by initial alcohol injections, all patients were followed to see if nodules recurred; additional alcohol injections were given when nodules were found. Two thirds of the patients also received treatment with interferon, and one third received alcohol injections without interferon. The researchers evaluated both groups to determine the timing of cancer recurrence and to see if survival rates differed between the groups. They also evaluated evidence for continued HCV infection with and without interferon treatment.

What did the researchers find?

The time to first recurrence of liver cancer did not differ in the two groups. However, second and third recurrences were less frequent in the patients receiving interferon. At 5 years after initial treatment, 68% of the interferon-treated patients were alive compared with 48% of the untreated patients. At 7 years, 53% of the interferon-treated group was alive compared with 23% of the untreated patients. Continuing HCV infection was greatly reduced in patients who received interferon; the virus persisted in all patients who did not receive interferon.

What are the limitations of the study?

Because the study is small and both patients and physicians knew the treatment regimen, results could have been unintentionally biased in favor of interferon treatment. Also, because participants had relatively mild HCV infections and mild liver abnormalities, the results cannot be used to predict outcomes in patients with more severe disease.

What are the implications of the study?

It may be possible to decrease the risk for liver cancer in patients with HCV infection by vigorously treating the infection.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Interferon Therapy Improves Survival in Patients with Liver Cancer and Hepatitis C Virus Infection. Ann Intern Med. 2003;138:I–52. doi: 10.7326/0003-4819-138-4-200302180-00003

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2003;138(4):I-52.

DOI: 10.7326/0003-4819-138-4-200302180-00003

©
2003 American College of Physicians
0 Citations

See Also

Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus
View MoreView Less

Related Articles

Effects of Long-Term Postoperative Interferon-α Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma: A Randomized, Controlled Trial
Annals of Internal Medicine; 134 (10): 963-967
Does Interferon-α Prevent Recurrence of Malignant Tumors in Patients with Hepatitis C–Related Liver Cancer?
Annals of Internal Medicine; 134 (10): I-7
Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection
Annals of Internal Medicine; 131 (9): 696-701
Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy
Annals of Internal Medicine; 127 (10): 875-881
View MoreView Less

Journal Club

Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1
Annals of Internal Medicine; 161 (10): JC11
Oral fingolimod was more effective than intramuscular interferon for relapsing–remitting multiple sclerosis
Annals of Internal Medicine; 152 (10): JC5-6
Review: Interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis B
Annals of Internal Medicine; 150 (8): JC4-11
View MoreView Less

Related Point of Care

Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
Hepatitis C
Annals of Internal Medicine; 157 (11): ITC6-1
Hepatitis C
Annals of Internal Medicine; 148 (11): ITC6-1
Multiple Sclerosis
Annals of Internal Medicine; 160 (7): ITC4-1
View MoreView Less

Related Topics

Gastroenterology/Hepatology
Gastrointestinal Cancer
Hematology/Oncology
Infectious Disease
Liver Cancer

Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Infectious Disease, Liver Cancer.

PubMed Articles

Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
J Gastroenterol 2018.
Acceptability and effectiveness of using mobile applications to promote HIV and other STI testing among men who have sex with men in Barcelona, Spain.
Sex Transm Infect 2018.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×